Related Experiment Video

Updated: Jul 15, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Next generation molecular targeted agents for breast cancer: focus on EGFR and VEGFR pathways

Kiyohiko Hatake1, Nahomi Tokudome, Yoshinori Ito

  • 1Division of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan. khatake@jfcr.or.jp

Breast Cancer (Tokyo, Japan)
|May 9, 2007
PubMed

Insights

Molecular targeting drugs like trastuzumab show promise for Her-2 positive metastatic cancers. Lapatinib offers hope for resistant cases and brain metastases, while bevacituzumab targets tumor growth pathways.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Metastatic and relapsed cancers, particularly Her-2 positive cases, present significant therapeutic challenges.
  • Existing treatments have limitations in efficacy and resistance development.

Purpose of the Study:

  • To review recent advancements in molecular targeting drugs for cancer treatment.
  • To highlight the efficacy of specific drugs against different cancer subtypes and resistance mechanisms.

Main Methods:

  • Literature review of recent progress in molecular targeting drugs.
  • Analysis of clinical responses to trastuzumab, lapatinib, erlotinib, and bevacituzumab.

Main Results:

  • Trastuzumab-based chemotherapy is effective for Her-2 positive metastatic or relapsed cases.
  • Lapatinib demonstrates potential efficacy against trastuzumab-resistant cancers and brain metastases.
  • Bevacituzumab may improve outcomes by targeting VEGF-VEGFR-associated tumor growth.

Conclusions:

  • Molecularly targeted therapies offer improved outcomes for specific cancer populations.
  • Trastuzumab, lapatinib, and bevacituzumab represent key advancements in personalized cancer treatment.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...